Skip to main content

Table 3 CSF biomarker levels by Aβ group

From: Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

 

Definition 1

(n = 318)

Definition 2

(n = 313*)

Definition 3

(n = 318)

Aβ-

Low burden

Aβ+

 

Aβ-

Low burden

Aβ+

 

Aβ-

Low burden

Aβ+

 

CSF- CL < 30

(n = 205, 64.5%)

CSF+ CL < 30

(n = 88, 27.7%)

CSF+ CL > 30

(n = 25, 7.86%)

P value

CSF- VR-

(n = 202, 64.5%)

CSF+ VR-

(n = 72, 23.0%)

CSF+ VR+

(n = 39, 12.5%)

P value

CL < 20

(n = 281, 88.4%)

20–40 CL

(n = 18, 5.66%)

CL > 40

(n = 19, 6.0%)

P value

p-tau (pg/ml)

13.9 (4.19)

16.5 (5.97)1

25.9 (6.94)1

<0.0001

13.8 (4.17)

16.2 (6.03)2

23.1 (7.40)1

<0.0001

14.6 (4.97)

19.6 (7.13)2

25.3 (7.08)1

<0.0001

t-tau (pg/ml)

176 (48.7)

202 (64.9)3

293 (71.6)1

<0.0001

176 (48.5)

199 (66.1)2

267 (75.1)1

<0.0001

183 (55.9)

239 (85.4)2

280 (65.8)1

<0.0001

NfL (pg/ml)

75.3 (23.6)

83.6 (23.4)4

114 (31.1)1

<0.0001

75.4 (23.7)

82.3 (22.9)

105 (31.4)1

<0.0001

77.4 (23.6)

98.5 (31.2)

112 (33.4)3

0.0004

Neurogranin (pg/ml)

722 (252)

802 (325)4

1103 (311)1

<0.0001

719 (251)

794 (330)

1019 (324)1

<0.0001

747 (282)

951 (402)4

1003 (239)2

0.0009

sTREM2 (ng/ml)

7.58 (1.93)

7.75 (2.15)

9.39 (2.83)2

0.006

7.57 (1.93)

7.74 (2.22)

8.83 (2.63)

0.053

7.63 (2.00)

8.84 (2.74)

8.79 (2.66)

0.065

YKL40 (ng/ml)

138 (44.8)

145 (49.8)

206 (58.5)1

0.0002

137 (44.6)

143 (51.4)

187 (58.5)3

0.002

140 (46.6)

170 (55.1)

200 (64.1)2

0.004

GFAP (ng/ml)

7.09 (2.13)

7.68 (2.32)

9.68 (2.58)3

0.001

7.08 (2.14)

7.67 (2.39)

9.00 (2.58)2

0.011

7.24 (2.22)

8.51 (1.91)

9.71 (2.74)2

0.004

IL6 (pg/ml)

3.86 (1.33)

3.81 (1.54)

3.97 (1.37)

0.33

3.87 (1.33)

3.90 (1.58)

3.72 (1.39)

0.89

3.86 (1.38)

3.66 (1.58)

3.94 (1.37)

0.56

S100B (ng/ml)

0.98 (0.20)

1.06 (0.26)

1.07 (0.25)

0.054

0.98 (0.20)

1.05 (0.25)

1.09 (0.27)

0.044

1.00 (0.21)

1.16 (0.33)

1.03 (0.18)

0.093

α-synuclein (pg/ml)

189 (80.9)

190 (62.5)

249 (87.3)2

0.005

189 (81.2)

184 (60.9)

239 (79.2)3

0.001

190 (76.6)

210 (82.3)

237 (85.1)

0.069

  1. Data are expressed as mean (M) and standard deviation (SD). One-way ANCOVA adjusted by age and sex, followed by Dunnett-corrected post hoc comparisons, was used to compare CSF biomarker values between groups. The P values indicated in the last column refer to the group main effect. Significant P values are marked in bold. All P values remained significant after FDR multiple comparison correction, except S100B in definition 2 (P = 0.055). “Low burden” refers to “low burden of Aβ pathology”. Abbreviations: Aβ amyloid-β, CL Centiloid, CSF cerebrospinal fluid, p-tau phosphorylated tau, t-tau total tau, NfL neurofilament light, S100B S100 calcium-binding protein B, sTREM2 soluble triggering receptor expressed on myeloid cells 2 (TREM2), GFAP glial fibrillary acidic protein, IL6 interleukin 6, VR visual read, YKL40 Chitinase-3-like protein 1
  2. *In definition 2, we included 313 participants because 2 participants did not have Aβ PET visual read assessment available and 3 additional participants had a discrepant CSF and visual read assessment (negative CSF Aβ42/40 ratio but positive visual read). Participants with this biomarker profile do not fall in any of the definition 2 categories
  3. 1P < 0.0001 vs Aβ- group
  4. 2P < 0.01 vs Aβ- group
  5. 3P < 0.001 vs Aβ- group
  6. 4P < 0.05 vs Aβ- group
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193